Claims

Claim 1

Use of an agent in the manufacture of a medicament for prevention or treatment of keratomycosis, wherein the agent comprises rapamycin or a salt thereof as an active ingredient and does not comprise amphotericin B, and the medicament is suitable for subconjunctival administration or eye instillation.

Claim 2

The use according to claim 1, wherein the agent comprises rapamycin or a salt thereof as a sole active ingredient.

Claim 3

The use according to claim 1 or 2, wherein the agent comprises polyethylene glycol.

Claim 4

The use according to claim 3, wherein a concentration of the polyethylene glycol is 80 to 99 % (w/w).

Claim 5

The use according to claim 3, wherein a concentration of the polyethylene glycol is 90 to 98 % (w/w).

Claim 6

The use according to any one of claims 3 to 5, wherein the polyethylene glycol is polyethylene glycol 400.

Claim 7

The use according to any one of claims 1 to 6, wherein the agent comprises ethanol.

Claim 8

The use according to any one of claims 1 to 7, wherein the medicament is suitable for subconjunctival administration, and a dosage form of the medicament is an injection.

Claim 9

The use according to any one of claims 1 to 7, wherein the medicament is suitable for eye instillation, and a dosage form of the medicament is eye drops.

Claim 10

The use according to claim 1, wherein:

a dosage form of the medicament is an injection;

a concentration of the rapamycin or the salt thereof comprised in the agent is 1 to 5 % (w/w); and

the agent comprises ethanol and polyethylene glycol 400, and a concentration of the polyethylene glycol 400 is 90 to 98

% (w/w), and wherein the medicament is suitable for subconjunctival administration.

Claim 11

The use according to claim 10, wherein:

the concentration of the rapamycin or the salt thereof comprised in the agent is 2 to 4 % (w/w);

a concentration of the ethanol is 4 % (w/w); and

the concentration of the polyethylene glycol 400 is 92 to 94 % (w/w).

Claim 12

The use according to any one of claims 1 to 11, wherein the medicament is suitable for administration at an interval of at least 5 or more days.

Claim 13

The use according to any one of claims 1 to 12, wherein a fungus(fungi) causing the keratomycosis is/are at least one selected from the group consisting of the genera *Candida*, *Fusarium*, *Saccharomyces*, *Penicillium*, and *Aspergillus*.

Claim 14

The use according to claim 13, wherein a fungus of the genus *Candida* is *C. albicans*.